Stewart Fisher - Feb 13, 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: Chief Scientific Officer
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Stock symbol: CCCC
Transactions as of: Feb 13, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/15/2023, 03:46 PM
Previous filing: Feb 1, 2023
Next filing: Aug 31, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Award	$0	+26K	+33.99%	$0.00	102K	Feb 13, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Stock Option (Right to Buy)	Award	$0	+125K		$0.00	125K	Feb 13, 2023	Common Stock	125K	$5.67	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024.
F2	The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023.